07:01 AM EDT, 03/20/2024 (MT Newswires) -- BioNTech (BNTX) reported Q4 earnings Wednesday of 1.90 euro ($2.06) per diluted share, down from 9.26 euros a year earlier.

Analysts polled by Capital IQ expected 2.65 euros.

Revenue for the quarter ended Dec. 31 was 1.48 billion euros, down from 4.28 billion euros a year earlier.

Analysts surveyed by Capital IQ expected 1.85 billion euros.

The company said it ended the quarter with 17.7 billion euros in cash, cash equivalents and security investments.

BioNTech said it expects 2024 revenue to be from 2.5 billion euros to 3.1 billion euros. Analysts surveyed by Capital IQ are expecting 3.07 billion euros.

Separately, BioNTech said it has appointed Annemarie Hanekamp as its chief commercial officer, effective July 1. She is joining the company from Novartis (NVS) and will succeed Sean Marett in this position.

Shares of the company were down more than 7% in recent Wednesday premarket activity.

Price: 87.15, Change: -6.97, Percent Change: -7.41